The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Investment will fund expansion to meet rising demand for CRDMO services
Subscribe To Our Newsletter & Stay Updated
